桂枝茯苓胶囊与西药治疗子宫肌瘤疗效比较(1)
【摘要】 目的：比较桂枝茯苓胶囊与西药治疗子宫肌瘤疗效。方法：选取2013年2月-2014年2月子宫肌瘤患者82例，按奇偶数字法分为观察组(41例)和对照组(41例)。对照组采用米非司酮治疗，观察组采用桂枝茯苓胶囊治疗，比较两组患者疗效。结果：两组患者治疗后子宫和肌瘤体积均明显缩小，组间比较差异无统计学意义(P>0.05)；观察组患者不良反应发生率及1年后复发率低于对照组，比较差异有统计学意义(P<0.05)。结论：桂枝茯苓胶囊与西药治疗子宫肌瘤均可达到缩小子宫与肌瘤体积的目的，但桂枝茯苓胶囊药物毒副作用小，不良反应发生率低，更利于提高患者用药安全性，值得临床借鉴与推广。
【关键词】 桂枝茯苓胶囊； 米非司酮； 子宫肌瘤
【Abstract】 Objective： To analyze the curative effect of Guizhi Fuling capsule compared with Western medicine in the treatment of uterine fibroids. Method： From February 2013 to February 2014 in the hospital，82 patients with uterine fibroids were randomly divided into the observation group (41 cases) and the control group (41 cases). The control group was treated by Mifepristone for treatment， and the observation group was treated by Guizhi Fuling capsule for treatment， the curative effects of the two groups were compared. Result： The uterine and fibroid volume of the two groups after treatment were significantly narrowed， but there were no significant differences between the two groups (P>0.05). The incidence of adverse reactions and the recurrence rate 1 year later of the observation group were lower than those of the control group， and the differences were statistically significant (P<0.05). Conclusion： Guizhi Fuling capsule and Western medicine in the treatment of uterine fibroids can achieve purpose of narrowing the uterine and fibroid volume， but the side effects of Guizhi Fuling capsule drug is small， the adverse reactions rate is low， more conducive to improving patients’ safety，is worthy of clinical reference and promotion.
, http://www.100md.com
【Key words】 Guizhi Fuling capsule； Mifepristone； Uterine myoma
First-author’s address：Traditional Chinese Medicine Hospital of Yongfeng County， Yongfeng 331500， China
doi：10.3969/j.issn.1674-4985.2015.32.032
子宫肌瘤在妇科临床上是最常见疾病类型之一，其多由子宫内平滑肌组织增生所致，与人体雌激素水平值相关[1]。在卵巢功能旺盛女性人群中发病较高。据相关资料报道，30～50岁患者人数在患者总数中约占80%左右[2]。临床根据肌瘤生长位置不同，将其分为3种类型，包括黏膜下肌瘤、浆膜下肌瘤和肌壁间肌瘤。子宫肌瘤发病初期，患者常无明显症状表现，但随着肌瘤体积增大，患者会出现月经量增多、痛经、经期延长、腹痛、腰酸等症状，严重时可导致患者出现继发性贫血、不孕等，严重影响女性患者身心健康[3]。为了探寻治疗该病症有效药物，本文选取子宫肌瘤患者82例，将其分为两组，分别采用米非司酮和桂枝茯苓胶囊治疗，并将两组患者治疗有效性与安全性进行对比。
, 百拇医药
1 资料与方法
1.1 一般资料 选取2013年2月-2014年2月子宫肌瘤患者82例，将其按奇偶数字法分为观察组41例与对照组41例。对照组患者年龄25～52岁，平均(38.7±3.6)岁；肌瘤直径1.3～4.6 cm，平均(2.8±0.6)cm；肌瘤类型：肌壁间肌瘤28例，浆膜下肌瘤6例，黏膜下肌瘤3例，混合型肌瘤4例。观察组患者年龄27～56岁，平均(39.1±3.9)岁；肌瘤直径1.2～4.5 cm，平均(2.6±0.5)cm；肌瘤类型：肌壁间肌瘤26例，浆膜下肌瘤8例；黏膜下肌瘤2例，混合型肌瘤5例。排除标准：子宫内膜癌患者、合并有严重内科疾病患者和语言沟通障碍患者。入选标准：知情同意参加本次试验患者。两组患者年龄、肌瘤直径、肌瘤类型比较，差异均无统计学意义(P>0.05)，具有可比性。, http://www.100md.com(钟惠兰)
【关键词】 桂枝茯苓胶囊； 米非司酮； 子宫肌瘤
【Abstract】 Objective： To analyze the curative effect of Guizhi Fuling capsule compared with Western medicine in the treatment of uterine fibroids. Method： From February 2013 to February 2014 in the hospital，82 patients with uterine fibroids were randomly divided into the observation group (41 cases) and the control group (41 cases). The control group was treated by Mifepristone for treatment， and the observation group was treated by Guizhi Fuling capsule for treatment， the curative effects of the two groups were compared. Result： The uterine and fibroid volume of the two groups after treatment were significantly narrowed， but there were no significant differences between the two groups (P>0.05). The incidence of adverse reactions and the recurrence rate 1 year later of the observation group were lower than those of the control group， and the differences were statistically significant (P<0.05). Conclusion： Guizhi Fuling capsule and Western medicine in the treatment of uterine fibroids can achieve purpose of narrowing the uterine and fibroid volume， but the side effects of Guizhi Fuling capsule drug is small， the adverse reactions rate is low， more conducive to improving patients’ safety，is worthy of clinical reference and promotion.
, http://www.100md.com
【Key words】 Guizhi Fuling capsule； Mifepristone； Uterine myoma
First-author’s address：Traditional Chinese Medicine Hospital of Yongfeng County， Yongfeng 331500， China
doi：10.3969/j.issn.1674-4985.2015.32.032
子宫肌瘤在妇科临床上是最常见疾病类型之一，其多由子宫内平滑肌组织增生所致，与人体雌激素水平值相关[1]。在卵巢功能旺盛女性人群中发病较高。据相关资料报道，30～50岁患者人数在患者总数中约占80%左右[2]。临床根据肌瘤生长位置不同，将其分为3种类型，包括黏膜下肌瘤、浆膜下肌瘤和肌壁间肌瘤。子宫肌瘤发病初期，患者常无明显症状表现，但随着肌瘤体积增大，患者会出现月经量增多、痛经、经期延长、腹痛、腰酸等症状，严重时可导致患者出现继发性贫血、不孕等，严重影响女性患者身心健康[3]。为了探寻治疗该病症有效药物，本文选取子宫肌瘤患者82例，将其分为两组，分别采用米非司酮和桂枝茯苓胶囊治疗，并将两组患者治疗有效性与安全性进行对比。
, 百拇医药
1 资料与方法
1.1 一般资料 选取2013年2月-2014年2月子宫肌瘤患者82例，将其按奇偶数字法分为观察组41例与对照组41例。对照组患者年龄25～52岁，平均(38.7±3.6)岁；肌瘤直径1.3～4.6 cm，平均(2.8±0.6)cm；肌瘤类型：肌壁间肌瘤28例，浆膜下肌瘤6例，黏膜下肌瘤3例，混合型肌瘤4例。观察组患者年龄27～56岁，平均(39.1±3.9)岁；肌瘤直径1.2～4.5 cm，平均(2.6±0.5)cm；肌瘤类型：肌壁间肌瘤26例，浆膜下肌瘤8例；黏膜下肌瘤2例，混合型肌瘤5例。排除标准：子宫内膜癌患者、合并有严重内科疾病患者和语言沟通障碍患者。入选标准：知情同意参加本次试验患者。两组患者年龄、肌瘤直径、肌瘤类型比较，差异均无统计学意义(P>0.05)，具有可比性。, http://www.100md.com(钟惠兰)